Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
तुलना करने के लिए मीट्रिक्स | ATXI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधATXIपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.1x | −1.0x | −0.5x | |
PEG अनुपात | 0.00 | −0.02 | 0.00 | |
क़ीमत/बुक | 0.3x | −0.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.6x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 361.5% | 45.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.4% | 8.6% | अनलॉक करें |